Coverage
-
October 16, 2023
Biotechnology company Longeveron Inc. and its investors on Monday saw a Miami federal judge give a final nod to a $1.4 million settlement agreement that ends claims the company overhyped the prospects for a drug it was developing as it was going public.
3 other articles on this case.
View all »